Page 3 - Dr Reddys

Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda

The partnership marks a strategic boost to Dr Reddy's oncology portfolio and expands Alvotech's biosimilar pipeline as Keytruda patents near expiry

Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment

Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were USD 29.5 billion. The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities, it stated. Subject to certain ...

Dr Reddy's Labs rallies 4%, hits over four-month high; here's why

Alvotech and Dr Reddy's entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.

Margin pressures, growth triggers to weigh on Dr Reddy's Laboratories

The stock has been an underperformer compared to peers not only in the short term (three months, and six months) but also in the longer term

Dr Reddy's: Brokerage reports by JM Financial, Motilal Oswal as stock up 4%

DRL's management has guided for double-digit growth in FY26, with margins expected to remain similar to FY25 levels. Here's what brokerages expect from the company going ahead

Dr Reddy's Q4 results: Profit rises 22% to ₹1,594 crore on record revenue

Dr Reddy's posts highest-ever quarterly revenue and profit in Q4 FY25 with strong growth in generics, PSAI and NRT acquisition; FY25 PAT up 2 per cent at ₹5,654 crore

Dr Reddy's Laboratories, Sanofi Healthcare partner for respiratory drug

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country

Dr Reddy's, Lupin recall products in US due to manufacturing errors: USFDA

Dr Reddy's Laboratories and Lupin are recalling products in the US market due to labelling and manufacturing errors, respectively, according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA) said a US-based subsidiary of the Hyderabad-based drug major is recalling certain batches of a generic antiepileptic drug in the US market. Princeton-based Dr Reddy's Laboratories, Inc is recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection (1,000 mg/100 mL) in the US due to labelling mix up, USFDA said. "The infusion bag is incorrectly labelled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL," it added. The company has issued the Class 1 nationwide (US) recall on March 13 this year, the US health regulator noted. As per the USFDA, a Class I recall pertains to .

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Senores Pharma to acquire 14 ANDAs from Dr Reddy's for US markets

Gujarat-based Senores Pharmaceuticals on Tuesday said it will acquire a basket of 14 Abbreviated New Drug Applications from Dr Reddy's Laboratories for an undisclosed amount. Senores Pharmaceuticals, Inc, USA, a subsidiary of the drug firm, has inked agreements with Dr Reddy's for acquiring the Abbreviated New Drug Applications (ANDAs), the company said in a statement. The basket includes 13 ANDAs approved by the USFDA (US Food and Drug Administration), with one application pending approval, it added. The addressable opportunity of the acquired ANDAs in the US is around USD 421 million as per IQVIA. Senores said the acquisition will be funded through the initial public offer proceeds. This is in line with the objects of the IPO stated in the Red Herring Prospectus, it added. Senores Pharmaceuticals MD Swapnil Shah said the acquired molecules span multiple therapeutic areas with growing consumption. The portfolio consists of controlled substances and the general category of produ

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Domestic funds' stake in this stock up over 2900% in FY25; check full list

DIIs have doubled their shareholding, in terms of absolute number of shares held, in 46 out of the Nifty 500 companies in the last nine months, shows ACE equity data.

'Optimistic' about Trump administration, says drugmaker Dr Reddy's

Earlier in the day, the generic drugmaker reported consolidated net profit of Rs 1,414 crore ($163.7 million) for the quarter ended Dec. 31

Dr Reddy's Labs Q3 results: PAT rises 2.5% at Rs 1,413 cr, revenue up 16%

The growth was largely driven by revenue from its recently acquired nicotine replacement therapy (NRT) portfolio and performance in the European and emerging markets

Dr Reddy's Lab Q3 results: Profit up 2.5% at Rs 1,413 cr, revenue rises 16%

Dr Reddy's Lab Q3 results: Shares of Dr Reddy's closed at Rs 1,289.35 on Thursday ahead of its results

Dr Reddy's Labs Q3 Preview: Revlimid to dent US sales, profits may rise 12%

Indian pharmaceutical (IT) major, Dr Reddy's Laboratories, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Thursday, January 23, 2025

Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'

Dr Reddy's up 15% in Dec so far; set for biggest monthly gain since Sep'20

Thus far in the month of December, Dr Reddy's share price has rallied 15%, its biggest monthly rally since September 2020, when it had surged 22%

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'